Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

February 13, 2020

Primary Completion Date

October 27, 2022

Study Completion Date

October 27, 2022

Conditions
Healthy
Interventions
DRUG

SKL24741

An inhibitor of voltage-gated sodium channels and a possible activator of Big Potassium channels. Administered as an oral dose in the form of a capsule or tablet.

DRUG

Placebo

Sugar pill manufactured to mimic SKL24741

Trial Locations (1)

53095

Spaulding Clinical Research, West Bend

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Spaulding Clinical Research LLC

OTHER

collaborator

Covance

INDUSTRY

lead

SK Life Science, Inc.

INDUSTRY